Tech Company Financing Transactions
Carbylan Therapeutics Funding Round
On 11/26/2007, Carbylan Therapeutics raised $20 million in Series B funding from Vivo Capital, Alta Partners and InterWest Partners.
Transaction Overview
Company Name
Announced On
11/26/2007
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from this round of financing will be used to advance Carbylan's lead product candidates based on chemically engineered polymers of hyaluronic acid. Carbylan's proprietary technology allows delivery of biomaterial-based medical devices as injectable liquids that self-polymerize, covalently bind to tissues at the target delivery site and, when combined with appropriate therapeutic agents, uniquely enable controlled drug release. The Company currently is conducting post-approval clinical studies for its first product AdvaCoat� Sinus Dressing, and a second generation device/drug combination product AdvaCoat� Rx for chronic rhinosinusitis will enter the clinic early next year. The company's second product, ActaVisc� - viscosupplement for intra-articular injection - will also enter the clinic early next year as a treatment for osteoarthritis.
Company Information
Company Status
Publicly-held
Industry
Medical Devices & Instruments
Mailing Address
3181 Porter Dr.
Palo Alto, CA 94304
USA
Palo Alto, CA 94304
USA
Phone
Website
Email Address
Overview
Carbylan was founded in 2005 to develop and market medical devices and device/drug combination products
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Renzi
Chief Financial Officer
Michael White
VP - R & D
David Gravett
VP - Regulatory Affairs
Hayley Lewis
Browse more venture capital transactions:
Prev: 11/26/2007: Achievers venture capital transaction
Next: 11/26/2007: Ceptaris Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs